非酒精性脂肪性肝病新药的临床研究进展

非酒精性脂肪性肝病(non-alcoholic fatty liver disease，NAFLD)是临床上最常见的慢性肝病，全球发病率约为25%，NAFLD可进展为肝纤维化、肝硬化和肝细胞癌，严重威胁人类健康。目前中国尚未批准任何治疗药物上市，新药研发迫在眉睫。NAFLD发病机制复杂，单一用药很难取得好的疗效。几种不同作用机制的药物联合使用是治疗NAFLD的必然趋势。通过联合用药可能降低药物的不良反应，发挥协同作用产生更好的疗效。本文综述了NAFLD新药联合用药的最新临床研究进展，以期为后续NAFLD新药开发和临床合理用药提供参考。

Nonalcoholic steatohepatitis (NASH)- current treatment recommendations and future developments

Non-alcoholic fatty liver disease(NAFLD) is the most common clinical chronic liver disease with a global incidence of about 25%, which could progress to liver fibrosis, liver cirrhosis, and hepatocellular carcinoma, and posing a serious threat to human health. At present, China has not approved any therapeutic drugs for marketing, and the research and development of new drugs is imminent. It is difficult to achieve great efficacy with a single medication due to the complex mechanism of NAFLD. The combination of several drugs with different pharmacological mechanisms is an inevitable trend for the future treatment of NAFLD, which is expected to reduce the adverse effects of the drug and play a synergistic effect to produce better efficacy. This paper reviews the latest clinical research progress of NAFLD combined drugs, so as to provide a reference for the subsequent new drug development and clinical rational drugs application of NAFLD.